DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
This Application is a National Stage entry of 371 of PCT/IB2023/054410 filed on April 28, 2023 - it claims priority of a Republic of Korea Application No. KR10-2022-0053712 filed on April 29, 2022.
Information Disclosure Statement
Two information disclosure statements (IDS) filed on October 29, 2024, and on June 23, 2026, are acknowledged and have been considered.
Status of the Claims
Acknowledgement is made of the claims in the filed Application 18/861,369.
Original claims 1-8, 10-11; amended claims 9, 12; cancelled claims 13-14. No new matter was added.
Thus, claims 1-12 are currently under consideration.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-4 and 9-12 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Fett and Venier WO 2021/204823 A1 (cited in the IDS), hereon after ‘823.
Regarding instant claims 1-4, ‘823 teaches compounds that are inhibitors of YAP1/TAZ-TEAD or TEAD dependent gene transcription. 823’ reveals an indole genus compound of formula (I) as shown (abstract and claim 1).
PNG
media_image1.png
83
183
media_image1.png
Greyscale
Compound of formula (I) in 823’ overlaps with instant compound of formula (I) where variables in instant claim 1 are as follows; Q is CH, X is C, Y is CRN, Z is N, R2 is H, L is absent or C1 alkylene, R1 is aryl wherein substituted with C1haloalkyl and W is
PNG
media_image2.png
79
91
media_image2.png
Greyscale
, where Ra, Rb and Rc are each H and R3 is H or C1 alkyl. Furthermore, Scheme 2 (page 15) in 823’ reveals exemplified embodiments (shown below) that read on instant compound of formula (I).
PNG
media_image3.png
87
153
media_image3.png
Greyscale
or
PNG
media_image4.png
137
243
media_image4.png
Greyscale
Regarding instant claims 9-12, reference 823’ teaches pharmaceutical compositions of compounds of formula (I) with pharmaceutically acceptable excipient (page 80 and claim 12) as in instant claim 9.
823’ further teaches compounds of formula (I) may be used in treatment of pathologies involving YAP1/TAZ-TEAD or TEAD dependent gene transcription inhibitors and for use as anticancer agent (page 80 and 88) as in instant claims 10 and 11. In addition, 823’ teaches the pharmaceutical compositions contain an effective dose of at least one of compound of formula (I), and in another aspect, a method of treating pathologies involving YAP1-TAZ-TEAD or TEAD dependent gene transcription inhibitors including examples of the diseases (page 80-81) – instant claim 12.
Thus, instant claims 1-4 and 9-12 are anticipated by Fett and Venier, WO 2021/204823 A1.
Claims 1-4 and 7 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Miller et a. WO 2022/ 049376 A1 (cited in the IDS), hereon after ‘376.
‘376 teaches example 39 (page 87), that reads on the instant claims as follows.
PNG
media_image5.png
90
119
media_image5.png
Greyscale
Wherein Q is CH, L is absent, Z is C, X is N, Y is N, R1 is H, R2 is C1 alkyl and W is
PNG
media_image6.png
73
96
media_image6.png
Greyscale
, where R3, Ra, Rb and Rc are each H.
Accordingly, instant claims 1-4 and 7 are anticipated by Miller et al., WO 2022/049376 A1.
Claims 1-4 and 7 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Spradlin et al. WO 2020/076996 A1 (cited in the IDS), hereon after ‘996.
‘996’ teaches the compound N-(1H-indol-4-yl)acrylamide (YP 1-19) ([0621] - page 244), which reads on the instant claims as follows.
PNG
media_image7.png
124
99
media_image7.png
Greyscale
Wherein Q is CH, L is absent, Z is C, X is N, Y is C, R1 is H, R2 is C1 alkyl and W is
PNG
media_image6.png
73
96
media_image6.png
Greyscale
, where R3, Ra, Rb and Rc are each H.
Claims 1-4 and 7 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by London et al. CA 3099847 A1 (cited in the IDS), hereon after ‘847.
847’ teaches compound GO1 (Table 1 – page 29) which reads on the instant claims as follows.
PNG
media_image8.png
124
101
media_image8.png
Greyscale
Wherein Q is CH, L is absent, Z is C, X is N, Y is N, R1 is H, R2 is H and W is
PNG
media_image6.png
73
96
media_image6.png
Greyscale
, where R3, Ra, Rb and Rc are each H.
Thus, instant claims 1-4 and 7 are anticipated by London et al. CA 3099847 A1.
Claims 1-4 and 7 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kokosza et al. 2014, (cited in the IDS) hereon after Kokosza.
Kokoza teaches compounds 10l and 10n (Table 1 page 557), which read on the instant claims, wherein Q is CH, L is absent, Z is C, X is N, Y is C, R1 is H, R2 is C1 alkyl and W is
PNG
media_image6.png
73
96
media_image6.png
Greyscale
, where R3, Ra, Rb and Rc are each H.
Therefore, instant claims 1-4 and 7 are anticipated by Kokosza et al. 2014.
Allowable Subject Matter
Claim 8 is allowed.
Conclusion
Claims 1-4, 7 and 9-12 are rejected.
Claims 5 and 6 are objected to because they are dependent on a rejected claim.
Claim 8 is allowed.
Communication
Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAULINE ONDACHI whose telephone number is (571)272-9419. The examiner can normally be reached Mon - Fri 8:00 am - 5:00 pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney L. Klinkel can be reached at (571)270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/P.O./Examiner, Art Unit 1627
/Kortney L. Klinkel/Supervisory Patent Examiner, Art Unit 1627
Prosecution Insights